Bremelanotide vs Alprostadil

Bremelanotide and alprostadil represent fundamentally different approaches to treating sexual dysfunction. Bremelanotide activates central melanocortin pathways to enhance sexual desire, while alprostadil provides peripheral vasodilation through prostaglandin signaling. Their mechanisms create complementary therapeutic profiles.

Mechanism of Action

Bremelanotide: Melanocortin Agonism (Central)

Bremelanotide is a synthetic melanocortin analog that activates central melanocortin receptors:

MC4R agonism (primary): Hypothalamic activation increases sexual desire and arousal
MC3R agonism (secondary): Contributes to appetite suppression and metabolic effects
Signaling: cAMP/PKA pathway in hypothalamic neurons
Downstream effects: Increased dopamine, decreased cortisol, enhanced sexual motivation

The melanocortin system acts upstream of dopaminergic sexual motivation circuits, making bremelanotide a “desire-initiating” agent rather than a peripheral erectogenic agent.

Alprostadil: Prostaglandin E1 (Peripheral)

Alprostadil (PGE1) directly relaxes cavernosal smooth muscle:

EP receptor activation: EP2, EP3, EP4 subtypes in corpus cavernosum
Adenylyl cyclase stimulation: Increases intracellular cAMP
Smooth muscle relaxation: Decreased intracellular calcium
Vasodilation: Increased arterial inflow and venous occlusion
Direct action: Bypasses neural and hormonal pathways entirely

Alprostadil provides immediate hemodynamic effects without requiring intact neurological pathways.

Central vs Peripheral Action

Parameter	Bremelanotide	Alprostadil
Primary site	Hypothalamus (central)	Corpus cavernosum (peripheral)
Neural requirement	Requires intact central pathways	Independent of neural function
Hormonal requirement	Modulates dopamine/cortisol	None — direct smooth muscle
Onset of sexual effect	Hours (desire component)	Minutes (erectile response)
Duration of effect	24-48 hours	1-4 hours
Psychological component	Enhanced desire/motivation	Mechanical vasodilation

Clinical Implications

Bremelanotide treats hypoactive sexual desire disorder (HSDD) by restoring central sexual motivation. Alprostadil treats erectile dysfunction (ED) through direct cavernosal vasodilation. They address different points in the sexual response cycle.

Male vs Female Efficacy

Bremelanotide: Female Sexual Dysfunction

FDA-approved: Vyleesi (2019) for premenopausal HSDD
Efficacy: Increased sexual desire events by 0.5-1.0/month vs placebo
FSD response rate: 25-30% achieve clinically meaningful improvement
Mechanism: Restores central sexual motivation in women
No effect on: Arousal lubrication (peripheral)

Bremelanotide: Male Sexual Dysfunction

Investigated: Not FDA-approved for male HSDD
Preclinical data: Enhances erectile function in animal models
Mechanism: MC4R activation increases sexual motivation in males
Clinical status: Phase 2 trials completed, no approval

Alprostadil: Male Erectile Dysfunction

FDA-approved: Caverject (injectable), MUSE (urethral suppository)
Efficacy: 60-70% response rate in ED
Mechanism: Direct cavernosal vasodilation
Limitations: Pain, priapism risk, injection site fibrosis
Onset: 5-15 minutes (injectable), 5-10 minutes (urethral)

Alprostadil: Female Sexual Dysfunction

Investigated: Not FDA-approved for female sexual dysfunction
Preclinical data: May improve genital blood flow
Clinical status: Limited data, not standard of care

Indication	Bremelanotide	Alprostadil
Female HSDD	FDA-approved	Not approved
Male HSDD	Investigational	Not approved
Female ED	Not primary indication	Investigational
Male ED	Investigational	FDA-approved

Onset and Duration

Parameter	Bremelanotide	Alprostadil (injectable)	Alprostadil (MUSE)
Route	SC injection	IC injection	Intraurethral
Onset	45-60 min	5-15 min	5-10 min
Peak effect	2-4 hours	10-30 min	15-30 min
Duration	24-48 hours	1-4 hours	30-60 min
Dosing	PRN (max 8x/month)	PRN	PRN

Side Effects

Bremelanotide Side Effects

Side Effect	Incidence	Mechanism
Nausea	40%	Central MC4R activation
Flushing	20%	Hypothalamic effects
Headache	15%	Central mechanism
Hyperpigmentation	5-10%	Melanocortin receptor activation
Vomiting	10%	Central mechanism
Injection site reactions	5%	Local irritation

Alprostadil Side Effects

Side Effect	Incidence	Mechanism
Penile pain	30-50%	Prostaglandin-mediated nociception
Priapism	1-3%	Excessive vasodilation
Hematoma/ecchymosis	10-15%	Injection trauma
Urethral burning (MUSE)	10-20%	Local PGE1 irritation
Penile fibrosis	2-5%	Chronic inflammation
Dizziness	5%	Systemic vasodilation

Key Differences

Bremelanotide’s side effects are predominantly central (nausea, flushing), while alprostadil’s are predominantly local (pain, injection site reactions). Bremelanotide causes hyperpigmentation through melanocortin receptor activation, a unique side effect profile.

Dosing Considerations

Bremelanotide (Vyleesi)

Dose: 1.75 mg SC injection
Frequency: Maximum once per 24 hours, maximum 8 doses/month
Administration: Self-injection 45 minutes before anticipated sexual activity
Contraindications: Uncontrolled hypertension, cardiovascular disease
Monitoring: Blood pressure (10-20 mmHg increase common)

Alprostadil (Caverject)

Dose: 1-40 mcg (titrate to effect)
Frequency: Maximum once per 24 hours
Administration: Self-injection into corpus cavernosum
Contraindications: Priapism predisposition, penile implants
Monitoring: Assess for priapism (>4 hours = emergency)

References

Clayton AH, et al. “Bremelanotide for hypoactive sexual desire disorder in premenopausal women.” J Clin Psychiatry 2017;78:1156-1163.
Goldstein I, et al. “Bremelanotide: new treatment for hypoactive sexual desire disorder.” Drugs 2019;79:501-512.
Linet OI, Ogrinc FG. “Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction.” NEJM 1996;334:873-877.
Padula-Waugh F, et al. “Prostaglandin E1 for erectile dysfunction.” Cochrane Database Syst Rev 2017;3:CD001784.
Clayton AH, et al. “Female sexual dysfunction.” Obstet Gynecol 2020;136:625-640.